Neutral
The article discusses the enterprise value to EBIT forward for Travere Therapeutics, Inc. (NASDAQ: TVTX), a company in the Pharmaceuticals: Major sect...
Bullish
Guggenheim analyst Vamil Divan maintained a 'Buy' rating for Travere Therapeutics (TVTX) and raised the price target to $65.00, reflecting confidence ...
Neutral
Travere Therapeutics (TVTX) stock reached a new 52-week high of $56.90, reflecting a 267% total return over the past year and a market capitalization ...